Highly purified cannabidiol (CBD) with a known and constant composition has proven to be an effective and safe therapeutic alternative for the treatment of drug resistant epilepsy [1,2]. The results of several randomized controlled clinical trials have allowed it to be approved by various drug regulatory entities as adjuvant therapy in patients older than 2 years with drug resistant epilepsy associated with Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex [3–7]. However, the mechanism of action of CBD in epilepsy, although not fully described, is multifactorial and is not exclusively related to the pathophysiology of these epileptic syndromes [8].
24
SEP
SEP
0